Skip to main content

Eisai Research to Use Genedata's Expressionist to Hunt Biomarkers

NEW YORK (GenomeWeb News) – The Eisai Research Institute will use Genedata’s Expressionist software in its biomarker discovery programs, Genedata said today.
 
The Expressionist platform integrates high-throughput data from transcriptomics, proteomics, metabolomics studies, and includes statistical analysis and interpretation functions.
 
Andover, Mass.-based ERI is a subsidiary of Japanese firm Eisai and is focused on several therapeutic programs, including studies of oncology, the central nervous system, and gastrointestinal diseases.
 
Financial terms of the agreement were not released.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.